S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)
S&P 500   4,567.18 (-0.06%)
DOW   36,124.56 (-0.22%)
QQQ   387.29 (+0.25%)
AAPL   193.42 (+2.11%)
MSFT   372.52 (+0.92%)
META   318.29 (-0.54%)
GOOGL   130.99 (+1.33%)
AMZN   146.88 (+1.41%)
TSLA   238.72 (+1.33%)
NVDA   465.66 (+2.33%)
NIO   7.43 (+1.37%)
BABA   72.39 (-0.88%)
AMD   118.38 (-0.16%)
T   17.22 (+3.36%)
F   10.60 (-0.93%)
MU   73.69 (-0.81%)
CGC   0.67 (-11.90%)
GE   120.24 (-1.06%)
DIS   90.80 (-1.32%)
AMC   7.03 (-6.15%)
PFE   29.09 (-0.65%)
PYPL   57.92 (-3.22%)
XOM   100.44 (-1.94%)

Silverback Therapeutics Stock Price, News & Analysis (NASDAQ:SBTX)

$5.21
0.00 (0.00%)
(As of 12/5/2023 ET)
Compare
Today's Range
$5.11
▼
$5.36
50-Day Range
$3.38
▼
$5.21
52-Week Range
$2.80
▼
$8.97
Volume
548,750 shs
Average Volume
337,931 shs
Market Capitalization
$187.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media

SBTX stock logo

About Silverback Therapeutics Stock (NASDAQ:SBTX)

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

SBTX Stock Price History

SBTX Stock News Headlines

May 11, 2023 | uk.investing.com
ARS Pharmaceuticals Inc (SPRY)
January 24, 2023 | seekingalpha.com
SPRY ARS Pharmaceuticals, Inc.
December 5, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
November 22, 2022 | 247wallst.com
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger
November 18, 2022 | nasdaq.com
Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics
November 10, 2022 | finance.yahoo.com
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
November 8, 2022 | finance.yahoo.com
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
October 28, 2022 | markets.businessinsider.com
Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions
December 5, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
October 21, 2022 | finance.yahoo.com
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
September 17, 2022 | markets.businessinsider.com
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
September 15, 2022 | seekingalpha.com
SBTX Silverback Therapeutics, Inc.
September 6, 2022 | markets.businessinsider.com
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
August 23, 2022 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
August 17, 2022 | apnews.com
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTX
August 11, 2022 | apnews.com
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTX
July 30, 2022 | morningstar.com
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations
July 28, 2022 | apnews.com
INVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
July 27, 2022 | benzinga.com
Shareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTX
July 26, 2022 | apnews.com
Lifshitz Law PLLC Announces Investigation of IEA, ZY, SBTX, and HNGR
July 26, 2022 | finance.yahoo.com
Silverback Therapeutics plans merger with San Diego biotech
July 25, 2022 | apnews.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HNGR, SBTX, U
July 22, 2022 | benzinga.com
SILVERBACK THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of SBTX and Encourages Investors to Contact the Firm
July 22, 2022 | prnewswire.com
SHAREHOLDER ALERT: Weiss Law Investigates Silverback Therapeutics, Inc.
July 22, 2022 | apnews.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HNGR, ONEM, SBTX, ZEN
July 22, 2022 | finance.yahoo.com
Once A Cancer Company, Silverback Merges With Small Biotech Working On Allergy Treatment
July 22, 2022 | marketwatch.com
Silverback Therapeutics Shares Down After Merger News
See More Headlines
Receive SBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
12/05/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SBTX
CUSIP
N/A
CIK
1671858
Web
www.silverbacktx.com
Phone
206 456 2900
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-89,480,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-29.62%
Return on Assets
-28.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
67.87
Quick Ratio
67.87

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.41 per share
Price / Book
0.70

Miscellaneous

Outstanding Shares
36,058,000
Free Float
23,654,000
Market Cap
$187.86 million
Optionable
Not Optionable
Beta
0.60
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Peter A. Thompson FACP (Age 62)
    M.D., Co-Founder & Chairman of Directors
    Comp: $5.12k
  • Mr. Jeffrey C. Pepe J.D.
    Ph.D., Interim CEO, Gen. Counsel & Corp. Sec.
  • Mr. Russ Hawkinson (Age 63)
    Sr. VP of Fin., Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Mr. Miguel Arcinas M.B.A.
    VP of Corp. Devel. & Investor Relations
  • Jen More
    Director of HR
  • Ms. Sue Hamke
    Sr. VP of Clinical Operations
  • Mr. Dario Gobunquin CPA
    Sr. Director of Accounting & Controller

Key Competitors

View All Competitors














SBTX Stock Analysis - Frequently Asked Questions

How have SBTX shares performed in 2023?

Silverback Therapeutics' stock was trading at $8.53 at the start of the year. Since then, SBTX shares have decreased by 38.9% and is now trading at $5.21.
View the best growth stocks for 2023 here.

How were Silverback Therapeutics' earnings last quarter?

Silverback Therapeutics, Inc. (NASDAQ:SBTX) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.65) earnings per share for the quarter, hitting the consensus estimate of ($0.65).

When did Silverback Therapeutics IPO?

(SBTX) raised $126 million in an IPO on Friday, December 4th 2020. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel served as the underwriters for the IPO and H.C. Wainwright was co-manager.

How do I buy shares of Silverback Therapeutics?

Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SBTX) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -